Table 4.

Geometric mean (CV%) [n] of active ADC exposures with BMS-986148 ± nivolumab (CA008-002).

		BMS-986148 monotherapy every 3 weeks				BMS-986148 + nivolumab every 3 weeks	BMS-986148 monotherapy once weekly
	Cyclea	0.4 mg/kg	0.8 mg/kg	1.2 mg/kg	1.6 mg/kg	0.8 mg/kg	0.4 mg/kg	0.6 mg/kg
C max, μg/mL (CV%) [n]	1	2.6 (76.1) [3]	15.8 (46.6) [8]	27.6 (21.6) [56]	40.0 (26.3) [10]	16.8 (26.3) [28]	8.8 (20.3) [8]	13.6 (31.0) [4]
	4	—	16.1 (72.2) [3]	25.3 (24.6) [15]	24.7 (10.5) [3]	16 (15.3) [7]	6.74 (20.4) [2]	—
AUCτ, μg·hour/mL (CV%) [n]	1	372 [1]	1093 (67.5) [8]	2304 (37.5) [54]	3238 (36.7) [10]	1320 (40.8) [27]	5.66 (30.1) [8]	1028 (33.4) [3]
	4	—	1283 (104) [3]	2377 (47.6) [14]	1851 (20.6) [3]	1671 (26.2) [6]	680 [1]	—

Abbreviations: ADC, antibody–drug conjugate; AUC_τ, area under the curve over the dosing interval; C_max, maximum concentration; CV, coefficient of variation.

^aCycle 1 is predose through 504 hours postdose.